Back to Webinars
Webinars

Beyond Amyloid: New Insights into Tau Pathology and Disease Progression with eMTBR

October 21, 2026
8:00 am PT / 11:00 AM ET / 5:00 PM CEST
Topic:
Neurology
REGISTER NOW

Presenters

  • Nicholas Ashton, PhD
    Sr. Director, Fluid Biomarker Program
    Banner Health
  • Sang Won Seo, MD
    Professor of Neurology
    Samsung Medical Center

Summary

As research into Alzheimer’s disease and other neurological conditions evolves, blood-based biomarkers are providing new opportunities to better understand tau pathology and how it relates to disease progression.

This webinar will examine emerging research on eMTBR-Tau as a blood-based marker of tau aggregation, including its relationship with tau PET staging and longitudinal clinical progression in Alzheimer’s disease. The discussion will also explore findings across other neurological conditions, offering a broader perspective on how tau-related biomarkers may help researchers characterize disease biology across different disease contexts.

What you’ll learn: 

  • How eMTBR-Tau relates to tau PET staging and longitudinal clinical progression in Alzheimer’s disease
  • What emerging research suggests about eMTBR-Tau across other neurological conditions
  • How blood-based biomarkers may help characterize tau pathology and disease progression across neurodegenerative disorders
REGISTER NOW
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.